Moral hazard in health insurance occurs when insurance coverage increases healthcare utilization because patients pay less than the full cost of care at the point of service. When the out-of-pocket price falls from the market price to a copayment or zero, patients consume care whose value to them is below its cost to produce — care that they would not have purchased at full price. The RAND Health Insurance Experiment (1974-1982), the most important experiment in health economics, demonstrated that cost-sharing significantly reduces utilization: patients assigned to free care used 25-30% more services than those with substantial cost-sharing. Critically, much of the additional utilization under free care was of low clinical value, though some was clinically important. The welfare implications are ambiguous: moral hazard generates deadweight loss (inefficient overconsumption), but cost-sharing may also deter valuable care, particularly among low-income and chronically ill populations.
Insurance exists to protect people from financial catastrophe — a $200,000 cancer treatment would bankrupt most families without coverage. But insurance creates a side effect: when someone else pays the bill, you use more of the product. This is moral hazard, and it is one of the central concepts in health economics because it creates a tension between the risk-protection function of insurance and the efficiency goal of consuming only care that is worth its cost.
The mechanism is straightforward. Without insurance, a patient facing a $500 specialist visit weighs the expected health benefit against $500. With insurance that requires only a $20 copay, the same patient weighs the benefit against $20. Many visits that are not worth $500 are worth $20, so utilization increases. The additional visits whose value falls between $20 and $500 represent the deadweight loss of moral hazard — care that costs more to produce than it is worth to the patient. The patient gains some benefit, but less than the cost, and the difference is a social loss.
The RAND Health Insurance Experiment provided definitive evidence. By randomly assigning families to different cost-sharing levels (eliminating selection bias), it showed that free care increased utilization by 25-30% compared to substantial cost-sharing. But the experiment also revealed that patients did not selectively reduce low-value care under cost-sharing — they reduced high-value preventive care and chronic disease management at roughly the same rate. Among the poorest, sickest participants, free care produced measurably better health outcomes. This finding complicates the simple deadweight-loss story: moral hazard generates waste, but cost-sharing designed to reduce moral hazard also deters beneficial care, with the greatest harm falling on vulnerable populations.
Modern insurance design attempts to navigate this tradeoff. Value-based insurance design (VBID) reduces cost-sharing for high-value services (preventive care, essential medications for chronic conditions) and increases it for low-value services (marginal imaging, brand-name drugs with generic equivalents). The idea is to align patient incentives with clinical value — removing the financial barrier to care that is worth its cost while maintaining deterrence of care that is not. This approach recognizes that moral hazard is not a uniform problem: the welfare consequences depend entirely on whether the additional utilization induced by insurance produces health value commensurate with its cost.